June 7, 2012 (Berlin, Germany) — New research has shown for the first time that serum biomarkers can predict progression of ankylosing spondylitis (AS) in patients already at high risk for progression ...

Ankylosing Spondylitis (AS) is increasingly affecting the young male population of India, with the condition most commonly found in men in their early 20s to 40s. Medical advancements have highlighted ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — According to data presented at the American College of Rheumatology Annual Meeting, NSAIDs and ...

For the first time for any biologic, data show almost 80 percent of ankylosing spondylitis (AS) patients on Cosentyx ® have no radiographic progression of the spine at 4 years[1] These new data also ...

Smoking and multiple epigenetic variables were found to be associated with radiographic progression in patients with ankylosing spondylitis, according to recently published data. A cohort of 76 ...

GHENT, Belgium — The progression of ankylosing spondylitis can be slowed when tumor necrosis factor (TNF) inhibitors are added to high-dose nonsteroidal anti-inflammatory drugs (NSAIDs), possibly ...

Physically demanding jobs may increase the effects of inflammation on the progression of ankylosing spondylitis, possibly leading to increased bone formation in these patients, according to new ...

Advances in medication have changed ankylosing spondylitis treatment and may even change the progression of the disease. That’s welcome news for many people who deal with the pain and stiffness of ...

Ankylosing spondylitis (AS) is usually detected clinically and classified by use of conventional radiography. Standard treatment for AS consists of nonsteroidal anti-inflammatory agents and ...

Featured in the June 2005 issue of <i>Arthritis & Rheumatism</i>, this study offers hope for decreasing the progression of AS, without increasing the risk of peptic ulcers or other adverse events. A ...

A study presented at EULAR 2012, the Annual Congress of the European League Against Rheumatism, has identified five biomarkers that may predict the progression of structural damage in the spine of ...

A sub-study showed up to 80% of ankylosing spondylitis (AS) patients treated with Cosentyx had no radiographic progression in the spine over two years[1] Cosentyx demonstrated a sustained response for ...